BioMind
Healthcare Software · Maryland, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1405 Bernerd Pl, Rockville, Maryland, 20...Phone Number
+65 65137725Website
www.biomind.aiRevenue
$7.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
2
1
1
About BioMind
BioMind specializes in advanced artificial intelligence solutions for the healthcare sector, focusing on medical imaging and diagnostics. Their products aim to enhance the accuracy and efficiency of disease detection and treatment planning. The company primarily serves hospitals, clinics, and healthcare professionals looking to integrate AI technology into their practices. BioMind is committed to improving patient outcomes through innovative technology and data-driven insights.Explore more
BioMind Org Chart
Get the full picture
Sign in to uncover key details.
LC
Research Engineer
BL
Senior DevOps Engineer
MS
Senior Research Engineer
LZ
Research Engineer
KW
Software Engineer
KN
Bioinformatics Software Developer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioMind your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on BioMind recently announced quarterly report
BioMind, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at BioMind
Check out if BioMind is spiking on competitors!
Funding: Get notified immidiatlly once BioMind has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if BioMind had a recent Job posting/layoffs
Product Launch: Get notified when BioMind launches new products
Check if BioMind has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at BioMind
Find 2 more new buyers
Company Profile Activity
Activity Insights
BioMind is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
BioMind is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about BioMind.
BioMind Tech Stack
A closer look at the technologies used by BioMind
BioMind News & Media
Biomind Labs Provides Corporate Update
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, provides a corporate update outlining its research and development, intellectual property and clinical trials initiatives. “The fourth quarter of 2023 holds immense significance for Biomind as we prepareBiomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine (“5-MeO-DMT”) organic synthesis scheme. This significant achievement marks a major breakthrough in the developBiomind Announces Voting Results From the 2023 Annual Meeting of Shareholders
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, today announced the results of matters voted on at its annual and special meeting of holders of common shares (“Shareholders”) held on Wednesday, June 28, 2023 (the “Meeting”). The voting results for eachBiomind Labs Announces Completion of Dosing in Phase II Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the completion of dose administration of 30 healthy subjects in the Company’s Phase II trial of its novel drug candidate BMND01
Read more news
Top Healthcare Software Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding BioMind
Sign Up For FreeTo access detailed company insights
BioMind specializes in advanced artificial intelligence solutions for the healthcare sector, focusing on medical imaging and diagnostics. Their products aim to enhance the accuracy and efficiency of disease detection and treatment planning. The company primarily serves hospitals, clinics, and healthcare professionals looking to integrate AI technol... Read More
